Effectiveness, Safety and Utilization of Vismodegib for Locally Advanced Basal Cell Carcinoma Under Real-world Conditions: Non-interventional Cohort Study JONAS


  • Martin Kaatz
  • Peter Mohr
  • Elisabeth Livingstone
  • Michael Weichenthal
  • Alexander Kreuter
  • Claudia Pföhler
  • Ulrike Leiter
  • Jens Ulrich
  • Jochen Sven Utikal
  • Ralf Gutzmer
  • Rudolf Herbst
  • Dirk Schadendorf Department of Dermatology, University Hospital Essen, Hufelandstr. 55, DE-45122 Essen, Germany




Locally advanced basal cell carcinoma, Vismodegib, Effectiveness, Safety, Non-interventional study, German ADOReg skin cancer registry


Most patients with advanced basal cell carcinomas (BCCs) may not benefit sufficiently from standard treatment comprising surgery and radiation. Vismodegib, an oral selective hedgehog pathway inhibitor, is approved for treatment of patients with locally advanced BCC inappropriate for surgery or radiotherapy, or for patients with symptomatic metastatic BCC. In order to enhance understanding of the effectiveness, safety and utilization of vismodegib in clinical practice in Germany, a non-interventional study, JONAS, was conducted. A total of 53 patients with locally advanced BCC who initiated treatment with vismodegib between 2016 and 2018 were included in the study, which was embedded in the German ADOReg skin cancer registry. Duration of response, the primary endpoint, was 12.4 months, progression-free survival 32.2 months and overall response rate 77.4%. Most adverse events were mild to moderate. Overall, results confirmed previous findings, demonstrating favourable responses and manageable safety of vismodegib in patients with locally advanced BCC in clinical practice.


Download data is not yet available.


Basal cell carcinoma overview. [accessed 2021 November 20] Available from: https://www.skincancer.org/skin-cancer-information/basal-cell-carcinoma/.

Campen S. 2019; Updated German guidelines for basal cell carcinoma. The Asco post. [accessed 2021 November 20] Available from: https://ascopost.com/News/59741.

Sekulic A, Mangold AR, Northfelt DW, LoRusso PM. Advanced basal cell carcinoma of the skin: targeting the hedgehog pathway. Curr Opin Oncol 2013; 24: 218-223.


Wadhera A, Fazio M, Bricca G, Stanton O. Metastatic basal cell carcinoma: a case report and literature review. How accurate is our incidence data? Dermatol Online J 2006; 12: 7.


Lo JS, Snow SN, Reizner GT, Mohs FE, Larson PO, Hruza GJ. Metastatic basal cell carcinoma: report of twelve cases with a review of the literature. J Am Acad Dermatol 1991; 24: 715-719.


Snow SN, Sahl W, Lo JS, Mohs FE, Warner T, Dekkinga JA, et al. Metastatic basal cell carcinoma: Report of five cases. Cancer 1994; 73: 328-335.


Reifenberger J, Wolter M, Weber RG, Megahed M, Ruzicka T, Lichter P, et al. Missense mutations in SMOH in sporadic basal cell carcinomas of the skin and primitive neuroectodermal tumors of the central nervous system. Cancer Res 1998; 58: 1798-1803.

Xie J, Murone M, Luoh SM, Ryan A, Gu Q, Zhang C, et al. Activating Smoothened mutations in sporadic basal-cell carcinoma. Nature 1998; 391: 90-92.


Göppner D, Leverkus M. Basal cell carcinoma: from the molecular understanding of the pathogenesis to targeted therapy of progressive disease. J Skin Cancer 2011; 650258.


Daya-Grosjean L, Couvé-Privat S. Sonic hedgehog signaling in basal cell carcinomas. Cancer Lett 2005; 225: 181-192.


LoRusso PM, Rudin CM, Reddy JC, Tibes R, Weiss GJ, Borad MJ, et al. Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res 2011; 17: 2502-2511.


Sekulic A, Migden MR, Basset-Seguin N, Garbe C, Gesierich A, Lao CD, et al. Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study. BMC Cancer 2017; 17: 332.


Basset-Séguin N, Hauschild A, Kunstfeld R, Grob J, Dréno B, Mortier L, et al. Vismodegib in patients with advanced basal cell carcinoma: Primary analysis of STEVIE, an international, open-label trial. Eur J Cancer 2017; 86: 334-348.


Gutzmer R, Schulze H-J, Hauschild A, Leiter U, Meier F, Haferkamp S, et al. Effectiveness, safety and utilization of vismodegib in locally advanced basal cell carcinoma under real- world conditions in Germany-the non-interventional study NIELS. J Eur Acad Dermatol Venerol 2021; 35: 1678-1685.


Summary of product characteristics, Erivedge 150 mg hard capsules. [accessed 2021 November 20] Available from: https://www.ema.europa.eu/en/documents/product-information/erivedge-epar-product-information_en.pdf.

Sekulic A., Migden MR, Oro AE, Dirix L, Lewis KD, Hainsworth JD, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med 2012; 366: 2171-2179.


Lear JT, Migden MR, Lewis KD, Chang ALS, Guminski A, Gutzmer R, et al. Long-term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30-month analysis of the randomized phase 2 BOLT study. J Eur Acad Dermatol Venerol 2018; 32: 372-381.


Dummer R, Ascierto PA, Basset-Seguin N, Dréno B, Garbe C, Gutzmer R, et al. Sonidegib and vismodegib in the treatment of patients with locally advanced basal cell carcinoma: a joint expert opinion. J Eur Acad Dermatol Venerol 2020; 34: 1944-1956.


Sekulic A, Migden MR, Lewis K, Hainsworth JD, Solomon JA, Yoo S, et al. Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC. J Am Acad Dermatol 2015; 72: 1021-1026.e8.



Additional Files



How to Cite

Kaatz, M., Mohr, P., Livingstone, E., Weichenthal, M., Kreuter, A., Pföhler, C., Leiter, U., Ulrich, J., Utikal, J. S., Gutzmer, R., Herbst, R., & Schadendorf, D. (2022). Effectiveness, Safety and Utilization of Vismodegib for Locally Advanced Basal Cell Carcinoma Under Real-world Conditions: Non-interventional Cohort Study JONAS. Acta Dermato-Venereologica, 102, adv00695. https://doi.org/10.2340/actadv.v102.293